tyrosine/necrosis

BACKGROUND OF THE INVENTION Technical Field The present disclosure relates to compounds having a tyrosine-based structure with prenyl group substitution and bearing properties for abrogating TRAIL resistance. A method for producing the compounds, and a pharmaceutical composition comprising one or

BACKGROUND OF THE INVENTION Technical Field The present disclosure relates to compounds having a tyrosine-based structure with prenyl group substitution and bearing properties for abrogating TRAIL resistance. A method for producing the compounds, and a pharmaceutical composition comprising one or

This invention pertains to sesquiterpene lactones and sesquiterpene lactone-containing plant extracts and preparations for pharmaceutical uses, particularly the use of sesquiterpene lactones for the treatment of severe inflammatory disorders, for example, sepsis, septic shock, or septicemia. A large

BACKGROUND OF THE INVENTION Technical Field The present disclosure relates to compounds having a tyrosine-based structure with prenyl group substitution and bearing properties for abrogating TRAIL resistance. A method for producing the compounds, and a pharmaceutical composition comprising one or

BACKGROUND OF THE INVENTION Memory loss has long been recognized as a common accompaniment of aging. The inabilities to recall the name of a recent acquaintance or the contents of a short shopping list are familiar experiences for everyone, and this experience seems to become more common as we

BACKGROUND OF THE INVENTION Memory loss has long been recognized as a common accompaniment of aging. The inabilities to recall the name of a recent acquaintance or the contents of a short shopping list are familiar experiences for everyone, and this experience seems to become more common as we

BACKGROUND OF THE INVENTION Memory loss has long been recognized as a common accompaniment of aging. The inabilities to recall the name of a recent acquaintance or the contents of a short shopping list are familiar experiences for everyone, and this experience seems to become more common as we

FIELD OF THE INVENTION This application relates to the field of antibody fragments derivatized with polymers, and in particular to the use of such derivatization to increase the circulation half-lives of antibody fragment-polymer conjugates. This application also relates to the use of such antibody

FIELD OF THE INVENTION This application relates to the field of antibody fragments derivatized with polymers, and in particular to the use of such derivatization to increase the circulation half-lives of antibody fragment-polymer conjugates. This application also relates to the use of such antibody

FIELD OF THE INVENTION This application relates to the field of antibody fragments derivatized with polymers, and in particular to the use of such derivatization to increase the circulation half-lives of antibody fragment-polymer conjugates. This application also relates to the use of such antibody

THE SEQUENCE LISTING The instant specification contains a sequence listing, hereby incorporated by reference, which was filed with the parent of the present application, U.S. patent application Ser. No. 12/850,490, in paper and in txt format on Dec. 30, 2010, the txt file being 84.6 kB in size. The

THE SEQUENCE LISTING Please enter into the specification the computer readable copy of the sequence listing filed with the present application in txt format on Dec. 30, 2010, being 84.6 kB in size. The Sequence Listing includes the sequences identified as SEQ ID NOs: 1 through 72. FIELD OF THE

FIELD OF THE INVENTION This application relates to the field of antibody fragments derivatized with polymers, and in particular to the use of such derivatization to increase the circulation half-lives of antibody fragment-polymer conjugates. This application also relates to the use of such antibody